Dapagliflozin vs Metformin for Type 2 Diabetes
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 994 (estimated)
- Sponsor
- The George Institute · Other
This trial is looking for adults with type 2 diabetes who want to explore a new treatment. Participants will take either dapagliflozin or metformin to see how well these medications work to help protect kidney function.
You may be able to join if
- I have been diagnosed with type 2 diabetes.
- I am 18 years or older.
- My body mass index is over 18.5.
- I am not currently on any diabetes medication or only taking metformin.
- My kidney function is healthy (eGFR is 45 or higher).
- I will provide my signed consent to join the trial.
You may not be able to join if
- I need quick treatment for high blood sugar.
- I have clear reasons not to take either metformin or dapagliflozin.
- I have documented coronary artery disease.
- I have documented heart failure.
- I am pregnant or breastfeeding.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.
Loading trial locations…